MaxLinear, Inc. (MXL) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] MaxLinear Inc (MXL) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, MaxLinear is a communications and connectivity chipmaker that looks like it may be coming out of a painful downcycle, but the stock has already moved so fast that the market is now pricing in a real recovery. > **📍 Basic Profile** > > Market Cap **$5.40 billion** · Semiconductors · NASDAQ NMS - GLOBAL MARKET · Price **$60.32** > **⚡ 3 Things You Should Know** > > 1. 📈 **Recovery story, not finished story:** The latest earnings and Q2 sales guidance were strong enough to trigger a huge stock jump, which tells you sentiment has flipped from “things are bad” to “maybe the bottom is in.” > > 2. ⚠️ **Core business still carries scars:** Even with the rebound excitement, MaxLinear’s trailing net margin is **-29.23%** and 3-year revenue growth is **-25.26%**, so this is not a clean, steady compounder yet—it’s more of a turnaround bet. > > 3. 🏷️ **Valuation now assumes better execution:** The stock is sitting near its 52-week high after a massive rally, and with no usable TTM PE because earnings are still negative, investors are effectively paying up today for a recovery that still has to be delivered. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin **-29.23%**, loss-making despite decent gross margin | > | Growth Rate | Slow🐢 | 3-year revenue growth **-25.26%**, though near-term momentum improved | > | Financial Health | Moderate💛 | Debt/equity **27.36%**, but current ratio only **1.34** and quick ratio **0.65** | > | Valuation | Pricey | PE **[Data unavailable]**, PS **11.55x**, price near 52-week high | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** MaxLinear designs semiconductor chips sold to communications, connectivity, broadband, and industrial customers, making money by shipping higher-performance analog/mixed-signal and connectivity components into networking and infrastructure systems. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Connectivity / broadband / communications semiconductors | [Data unavailable] | ↑ | Recent product and guidance news suggest demand is improving after a weak stretch | | Industrial connectivity expansion | [Data unavailable] | ↑ | New RS-485 / RS-422 transceiver launch shows management is trying to widen end-market exposure | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 56.84% | Top tier for many chip peers | What’s interesting is the product economics are still pretty solid | | Net Margin | -29.23% | Below Average | In other words, gross profit isn’t flowing through because the company is still carrying too much cost versus current revenue | | ROE | -28.80% | Below Average | Negative returns on equity usually mean shareholders are funding a weak part of the cycle rather than benefiting from scale | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing, with signs of rebound | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | Recent outlook improving, long-term still weak | | Profit Growth | [Data unavailable] | [Data unavailable] | Improving on an EPS basis, but still not strong enough to support TTM profitability | **Growth Quality:** > Worth noting, the recent excitement appears tied to stronger Q1 results and upbeat Q2 sales guidance, which is better than a purely hype-driven move. But the longer-term numbers still look rough, so this recovery needs to become sustained revenue growth—not just one good quarter and a relief rally. --- #### 💰 Financial Health Check **One Sentence:** Think of it like someone with manageable long-term debt, but cash liquidity is a bit tighter than you’d like for a business coming off a downturn. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 27.36% | <60% safe | ✅Safe | | Current Ratio | 1.34 | >1.5 healthy | ⚠️Tight | | Cash Flow | Positive (cash flow/share **0.86**) | >0 | ✅Positive | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $9.07 - 52-Week High: $63.52 - Current: $60.32, **very close to high** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | | | ●(**94%** position) | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE **[Data unavailable]** | 5-year avg **[Data unavailable]** | [Data unavailable] | | vs Peers | PS **11.55x** | Industry avg **[Data unavailable]** | [Data unavailable] | **What the Current Valuation is Betting On:** > Basically, it means the market is betting the recent earnings improvement is the start of a broader semiconductor recovery for MaxLinear, not a one-off quarter. At this level, investors seem to be assuming margins recover meaningfully and new products plus improving demand can rebuild earnings power. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04-24 | Strong Q1 results and high Q2 sales guidance drove shares sharply higher | **Positive** — this is the main reason sentiment changed so quickly | | 2026-04-24 | Needham upgraded MXL to Buy with $60 target; Stifel kept Buy and raised target to $49 | **Positive** — analysts are becoming more constructive, though the stock already ran to around Needham’s target | | 2026-03-25 | MaxLinear expanded industrial connectivity portfolio with new transceivers | **Neutral to Positive** — not a game changer by itself, but it supports diversification beyond the weakest pockets of demand | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 56.84% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -29.23% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -28.80% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↓ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2026-03-31 | $0.18 | $0.22 | +22.4% Beat 😀 | | 2025-12-31 | $0.18 | $0.19 | +5.1% Beat 😀 | | 2025-09-30 | $0.12 | $0.14 | +16.5% Beat 😀 | | 2025-06-30 | $0.02 | $0.02 | +9.9% Beat 😀 | **Earnings Trend Interpretation:** Four straight beats usually tell you management is either executing better than feared or that the market had gotten too pessimistic. In MaxLinear’s case, it looks more like expectations were deeply depressed and the company is now proving the downturn may be easing. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 7 firms | 46.7% | | Hold | 8 firms | 53.3% | | Sell | 0 firms | 0% | **Target Price:** $49 ~ $60 (Median **$54.50**) **vs Current Price:** roughly **9.6% downside risk** versus median target **Insider Activity:** Net **selling** in past 3 months > What you might care about is that insider selling is not automatically bearish—some of these filings look tied to option exercises or tax-related transactions. Still, there was also open-market selling by an executive in March, so it’s not a strong confidence signal right when the stock has surged. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Turnaround Risk:** Recent momentum may fade if Q2 strength doesn’t continue → If this happens, the stock could give back gains because expectations reset upward very quickly 2. **Profitability Risk:** Gross margin is healthy, but operating and net margins are still deeply negative → If this happens, revenue recovery may not translate into shareholder returns soon 3. **Volatility Risk:** Beta is **3.39**, which is very high → If this happens, even good companies can see brutal swings, especially around earnings and semiconductor cycle sentiment --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** MaxLinear is a semiconductor name tied to communications and connectivity markets that now looks more like a cyclical recovery story than a stable quality compounder. > > **Key strength:** The encouraging part is that gross margins remain strong and the company just delivered better-than-expected results with upbeat guidance, which suggests the business may be exiting its worst phase. > > **Key risk:** The big concern is that the stock has already surged near its 52-week high while trailing profitability is still negative, so there’s not much room for disappointment. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis